• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

The Mumbai-based small-cap pharma firm Indoco Remedies touched its 52-week high early this week at Rs 412 on the buzz that the company was in talks with 2-3 companies in Germany and the UK for acquisitions. Dealers said Indoco was looking at companies that have wide range of IP products that could be marketed in the regulated markets of Europe and the US.

A recent research report by Networth Stock Broking was bullish on the company. Analysts of Networth Stock Broking said Indoco has recently signed a supply agreement with a German player and its facility is about to be approved by German regulatory authorities soon.

"As per the deal, Indoco will supply its 18 branded formulations to Germany. This deal of 18 products is believed to generate sales worth Rs. 8 crore per annum," the report said.

Rajesh Abraham

More Stories on : Stocks | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Motilal Oswal offers 9% stake to foreign equity investors

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line